provider image
Welcome! You’re in GoodRx for healthcare professionals. Now, you’ll enjoy a streamlined experience created specifically for healthcare professionals.
Skip to main content

Lumakras

sotorasib
Used for Lung Cancer
Used for Lung Cancer

Lumakras (sotorasib) is a medication that’s used for metastatic non-small cell lung cancer (NSCLC). In particular, it’s used for adults who have a specific mutation called KRAS G12C in their lung cancer. Lumakras (sotorasib) is typically recommended only when first-choice treatment doesn’t work anymore. It can be a convenient option since it’s taken by mouth once a day. But, it commonly causes bothersome side effects, like stomach upset and fatigue.

Reviewed by:
reviewer
Julia Lee, PharmD, BCOP
reviewer
Cydnee Ng, PharmD
Last reviewed on June 1, 2023
BasicsSide effectsPros & consPharmacist tipsFAQsWarningsDosageAlternativesLatest newsReferencesPricesMedicare
basics-icon

What is Lumakras (sotorasib)?

What is Lumakras (sotorasib) used for?

  • Metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, after having tried at least one previous cancer treatment

How Lumakras (sotorasib) works

Lumakras (sotorasib) is a KRAS G12C inhibitor. KRAS is a protein in your body that sends signals to your cells to grow and divide. In certain lung cancers, a mutation (change) in KRAS called G12C leads to uncontrolled cell growth. Lumakras (sotorasib) attaches to KRAS proteins with the G12C mutation. By doing so, the medication helps block tumor growth.

Drug Facts

Common BrandsLumakras
Drug ClassKRAS G12C inhibitor
Controlled Substance ClassificationNot a controlled medication
Generic StatusNo lower-cost generic available
AvailabilityPrescription only
basics-icon

What are the side effects of Lumakras (sotorasib)?

The following side effects may get better over time as your body gets used to the medication. Let your healthcare provider know immediately if you continue to experience these symptoms or if they worsen over time.

Common Side Effects

  • Diarrhea (42%)
  • Muscle or bone pain (35%)
  • Fatigue (26%)
  • Nausea (26%)
  • Cough (20%)

Other Side Effects

  • Vomiting
  • Constipation
  • Stomach pain
  • Shortness of breath
  • Swelling

Serious Side Effects

Contact your healthcare provider immediately if you experience any of the following.
  • Liver injury: pain in the right side of the stomach, yellowing of the eyes or skin, dark or brown urine
  • Lung damage: cough, shortness of breath, fever

Source: DailyMed

The following side effects have also been reported

Side effects that you should report to your care team as soon as possible:

  • Allergic reactions—skin rash, itching, hives, swelling of the face, lips, tongue, or throat
  • Dry cough, shortness of breath or trouble breathing
  • Liver injury—right upper belly pain, loss of appetite, nausea, light-colored stool, dark yellow or brown urine, yellowing skin or eyes, unusual weakness or fatigue

Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):

pros-and-cons

Pros and cons of Lumakras (sotorasib)

thumbs-up

Pros

Oral medication that’s taken once a day

Targeted therapy option for people with metastatic non-small cell lung cancer with a KRAS G12C mutation

thumbs-down

Cons

Commonly causes diarrhea, nausea, muscle pain, and fatigue

Only recommended after first-choice treatment hasn’t worked

pharmacist-tips

Pharmacist tips for Lumakras (sotorasib)

pharmacist

  • The full dose of Lumakras (sotorasib) is 960 mg once a day. In order to make the 960 mg dose, you’ll need three 320 mg tablets or eight 120 mg tablets. Take the entire dose at once each day. You don’t need to spread out the tablets throughout the day.

    • Swallow Lumakras (sotorasib) tablets whole. Don’t cut or crush the tablets.

      • If you’re having trouble swallowing Lumakras (sotorasib) tablets, you can place your dose in a glass with 4 ounces (120 mL) of room-temperature tap water. Stir or swirl the cup for about 3 minutes until the tablets break up into small pieces (the tablets won’t dissolve completely). Drink the mixture right away, and don’t chew any solid tablet pieces. Add another 4 ounces (120 mL) of water to the glass, swirl the mixture, and drink. This makes sure you’ve taken all of the medication for your dose.

        • If you need to take medication for heartburn, avoid medications like omeprazole (Prilosec) and famotidine (Pepcid AC) while you’re taking Lumakras (sotorasib). These medications might make Lumakras (sotorasib) not work as well. Instead, you can use an antacid like Tums. Just make sure to take Lumakras (sotorasib) 4 hours before or 10 hours after the antacid so the medications don’t interfere with each other.

          • If you’re starting any new medications, supplements, or herbal products, talk with your provider or pharmacist first to make sure they’re safe to take with Lumakras (sotorasib). Lumakras (sotorasib) can interact with other medications and supplements. Depending on what the specific interaction is, this can affect your risk of side effects or how well your medications work. For example, taking rosuvastatin (Crestor) with Lumakras (sotorasib) can possibly raise your risk of side effects from the cholesterol medication like joint pain or headache.

            • Talk with your provider or pharmacist about handling Lumakras (sotorasib) safely. Store the medication away from children and pets.

              faqs

              Frequently asked questions about Lumakras (sotorasib)

              How do I know whether Lumakras (sotorasib) is right for me?
              Lumakras (sotorasib) is only approved for people with a KRAS G12C mutation in their lung cancer. The lung cancer must also be considered advanced or metastatic, meaning that it has started to spread outside of the lung. To determine whether your lung cancer has the KRAS G12C mutation, your provider will collect a sample of your tumor tissue (biopsy) or order a blood test. If your lung cancer has this mutation, Lumakras (sotorasib) might be a treatment option for you, especially if first-choice treatment is no longer working.
              How long should I take Lumakras (sotorasib)?
              Talk with your provider about how long you should take Lumakras (sotorasib). Usually, you’ll continue taking Lumakras (sotorasib) until the cancer starts growing again, meaning the medication is no longer working for you. You might also stop Lumakras (sotorasib) if you have too many side effects from the medication, like diarrhea, nausea, and fatigue. If you’re not able to take the medication because of side effects, let your healthcare team know. They might lower the dose or recommend that you take other medications to help manage side effects before they consider stopping Lumakras (sotorasib).
              Why can’t I take certain heartburn medications with Lumakras (sotorasib)?
              Your body absorbs Lumakras (sotorasib) best in your stomach where it’s acidic. Heartburn medications like famotidine (Pepcid AC) and omeprazole (Prilosec) make the stomach less acidic. With less acidic conditions, your body isn’t able to absorb Lumakras (sotorasib) as well. And if less Lumakras (sotorasib) is absorbed by the body, it might not work as well. If you have heartburn while you’re taking Lumakras (sotorasib), it’s okay to use an antacid like Tums. Be sure to take Lumakras (sotorasib) 4 hours before or 10 hours after the antacid. That way, the medications don’t interfere with each other.
              What should I do if I miss a dose of Lumakras (sotorasib)?
              If you miss your Lumakras (sotorasib) dose by more than 6 hours, skip the missed dose, and take your next dose at your regular time the next day. Don’t take two doses at the same time to make up for the dose you missed. You should take Lumakras (sotorasib) at the same time each day to make sure the medication works at its best for you. Making a habit of taking Lumakras (sotorasib) at the same time every day might also help you remember to take your medication.
              What should I do if I vomit after taking a dose of Lumakras (sotorasib)?
              If you vomit after taking a dose of Lumakras (sotorasib), don’t take another dose that day to make up for it. Take your next dose at the regular time the next day. If you’re not able to take Lumakras (sotorasib) because of vomiting or nausea from the medication, talk with your provider. They can prescribe medications to help prevent or manage vomiting or nausea. If your nausea and vomiting are still bothersome after trying medications, your provider might lower your Lumakras (sotorasib) dose.
              I heard Lumakras (sotorasib) was an accelerated approval. What does that mean?
              The accelerated approval pathway is a program that the U.S. FDA uses to help speed up the lengthy medication approval process to fill an unmet medical need. In this approval pathway, the FDA looks at evidence that the medication can improve a surrogate endpoint (a measurement that’s thought to reflect a clinical benefit, like living better or longer). But, the FDA requires the manufacturer to do more studies to confirm that people truly gain clinical benefit from the medication. Lumakras (sotorasib)’s accelerated approval was based on a study of people with advanced or metastatic NSCLC and the KRAS G12C mutation who had tried at least one cancer treatment. In that study, 36% of those taking Lumakras (sotorasib) had shrinkage of their tumors (the surrogate endpoint). This accelerated approval is important because there were previously no specific treatment options available for lung cancer with the KRAS G12C mutation.
              GoodRxEducationalIcon

              How to save using GoodRx

              Compare Prices
              1. Compare PricesSpecify your dosage and quantity to find out exactly how much you can save.
              Select your free coupon
              2. Select your free couponYou can use the displayed coupon, or compare prices at other pharmacies near you.
              Show coupon to your pharmacist
              3. Show coupon to your pharmacistPresent your printed or electronic coupon when you pick up your prescription.
              Get free couponLearn more
              warings-icon

              What are the risks and warnings for Lumakras (sotorasib)?

              Lumakras (sotorasib) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.

              risk-warning

              Liver injury

              Lumakras (sotorasib) might cause damage to your liver. Because of this risk, you’ll need to get blood tests done so your healthcare provider can track how well your liver is working. You’ll typically need these blood tests before you start Lumakras (sotorasib), every 3 weeks when you first start, and then less often after that. In studies, some people experienced liver injury within the first 2 months of starting Lumakras (sotorasib). Let your healthcare team know if you notice signs of liver damage, such as pain in the right side of the stomach, yellowing of the eyes or skin, or dark or brown urine. If your provider suspects that you have liver damage, your provider might have you take a break from Lumakras (sotorasib). Once your liver test results return to normal, you might be able to restart the medication at a lower dose.

              risk-warning

              Lung damage

              Although rare, Lumakras (sotorasib) can cause damage to the lungs, which can sometimes be life-threatening. In studies, lung problems started within the first 4 months of taking Lumakras (sotorasib). Let your healthcare team know if you experience new or worsened cough, shortness of breath, or fevers. You’ll probably need to stop the medication while your provider checks your lungs for problems.

              dosage

              Lumakras (sotorasib) dosage forms

              Typical dosing for Lumakras (sotorasib)

              The typical dose is 960 mg by mouth once a day, with or without food.

              Lumakras (sotorasib) is available as 120 mg and 320 mg tablets. The daily dose is taken as eight 120 mg tablets or three 320 mg tablets at one time each day.

              alternatives

              What are alternatives to Lumakras (sotorasib)?

              There are a number of medications that your doctor can prescribe in place of Lumakras (sotorasib). Compare a few possible alternatives below.
              Lumakras (sotorasib)
              Used for:

              • Metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, after having tried at least one previous cancer treatment

              View Prices
              Krazati (adagrasib)
              Used for:

              • Locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation, after having tried at least one previous cancer treatment

              • Locally advanced or metastatic colorectal cancer with a KRAS G12C mutation, together with Erbitux (cetuximab), after having tried certain previous cancer treatments

              $22509.14 Lowest GoodRx priceView Prices

              Get savings updates for Lumakras (sotorasib)

              Receive price alerts, news, and other messages from GoodRx about Lumakras (sotorasib) and other healthcare topics and relevant savings offers.

              By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.

              References

              Best studies we found

              American Cancer Society. (2019). Targeted therapy safety.

              American Cancer Society. (2023). If you have non-small cell lung cancer.

              American Cancer Society. (2023). Targeted drug therapy for non-small cell lung cancer.

              View All References (11)

              American Cancer Society. (2023). Tests for lung cancer.

              American Lung Association. (2022). KRAS and lung cancer.

              Amgen Inc. (n.d.). About KRAS G12C in NSCLC.

              Amgen, Inc. (n.d.). About Lumakras®.

              Amgen Inc. (2023). Lumakras- sotorasib tablet, coated [package insert]. DailyMed.

              Nakajima, E. C., et al. (2022). FDA approval summary: Sotorasib for KRAS G12C-mutated metastatic NSCLC. Clinical Cancer Research.

              National Cancer Institute. (n.d.). Mutation.

              National Cancer Institute. (n.d.). Surrogate endpoint.

              National Comprehensive Cancer Network. (2023). Metastatic non-small cell lung cancer.

              Skoulidis, F., et al. (2021). Sotorasib for lung cancers with KRAS p.G12C mutation. The New England Journal of Medicine.

              U.S. Food and Drug Administration. (2021). FDA grants accelerated approval to sotorasib for KRAS G12C mutated NSCLC.

              GoodRx Health has strict sourcing policies and relies on primary sources such as medical organizations, governmental agencies, academic institutions, and peer-reviewed scientific journals. Learn more about how we ensure our content is accurate, thorough, and unbiased by reading our editorial guidelines.
              Was this page helpful?

              Browse medications

              View All

              Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.